Nayzilam generic
Nayzilam is an anti-epileptic drug owned by Ucb Inc. The active ingredient in Nayzilam is midazolam. The drug was first authorized for market use on 17 May, 2019. Nayzilam is available in spray and nasal dosages and has a total of 4 patents.
When will Nayzilam generic be available?
The generics of Nayzilam are expected to be released after 18 January, 2028. This date corresponds to the expiry date of the last patent on Nayzilam.
Nayzilam uses
The active ingredient in Nayzilam, midazolam, makes it an effective treatment for episodic seizures. It is used for acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern. It is approved for use in patients with epilepsy who are 12 years of age and older.
Nayzilam patent expiration
Nayzilam holds a total of 4 drug patents. These patents are primarily focused on the methods and compositions for the delivery of a therapeutic agent. The last expiration date of Nayzilam patents falls on 18th January, 2028, after which Nayzilam generic drugs can be released. Below are the details of the patents: